Trials / Recruiting
RecruitingNCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 146 (estimated)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Conditions
- B-cell Malignancy
- Non-Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Waldenström Macroglobulinemia
- Marginal Zone Lymphoma
- Follicular Lymphoma
- DLBCL Unclassifiable
- Richter's Transformation
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-16673 | Orally administered |
Timeline
- Start date
- 2022-05-06
- Primary completion
- 2029-01-31
- Completion
- 2029-01-31
- First posted
- 2022-03-24
- Last updated
- 2026-04-17
Locations
29 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05294731. Inclusion in this directory is not an endorsement.